Archive - NewLimit Blog

September // October 2024 Progress Update

In chimerico reprogramming

Nov 11, 2024 •

Jacob C. Kimmel

September 2024

July // August 2024 Progress Update

Completing the discovery cycle

Sep 16, 2024 •

Jacob C. Kimmel

July 2024

May // June 2024 Update

Reversing phenotypic age

Jul 5, 2024 •

Jacob C. Kimmel

June 2024

Markus Grompe is joining our Scientific Advisory Board

We’re excited to announce that Markus Grompe is joining our Scientific Advisory Board to support our Metabolism program.

Jun 11, 2024 •

Jacob C. Kimmel

May 2024

2024 May Progress Update - Live Event!

The days are long, the years are short

May 10, 2024 •

Jacob C. Kimmel

March 2024

January 2024

2023 Year in Review

Construction ends. The search begins.

Jan 9, 2024 •

Jacob C. Kimmel

November 2023

September-October 2023 Progress Update

Expanding the palette & compounding returns

Nov 13, 2023 •

Jacob C. Kimmel

September 2023

July-August 2023 Progress Update

Recursive record setting

Sep 5, 2023 •

Jacob C. Kimmel

July 2023

May-June 2023 Progress Update

Jul 7, 2023 •

Jacob C. Kimmel

May 2023

NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors

NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging

May 16, 2023 •

Brian Armstrong

,

,

, and

Jacob C. Kimmel

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts